Not yet reviewed — this article is pending editorial review by Lyrea.
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
CRL-40-940
Flmodafinil (CRL-40,940) is a wakefulness-promoting agent related to modafinil, developed by NLS Pharma for conditions including chronic fatigue syndrome, idiopathic hypersomnia, narcolepsy, ADHD, and Alzheimer's disease. It acts as a selective atypical dopamine reuptake inhibitor and, unlike modafinil, does not induce cytochrome P450 enzymes. Patented in 2013, it is sold online as a research chemical and used non-medically as a nootropic.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Duration
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
CRL-40-940 is used non-medically as a nootropic, and its documented action is the promotion of wakefulness. In comparison studies it sustained wakefulness over a longer timeframe than modafinil while disturbing sleep architecture less, and it was not followed by sleep rebound. The available material characterizes it as a wakefulness-promoting and cognitive-enhancement agent rather than describing a distinct subjective character.
Physical
Wakefulness promotion is the primary attested physical effect, described as maintained over an extended period without subsequent sleep rebound.
Cognitive
Reported use centers on cognitive enhancement, with no further detail available on headspace, emotional tone, or thought patterns.
Pharmacology
Pharmacodynamics
Flmodafinil acts as a selective atypical dopamine reuptake inhibitor, binding the dopamine transporter (DAT) with a Ki of 4,090 nM and blocking it by roughly 83%, a greater degree of blockade than methylphenidate without accompanying adrenergic effects. Its affinity for the serotonin transporter is around 12-fold weaker (Ki 48,700 nM), and it has negligible affinity for the sigma σ1 receptor (Ki > 100,000 nM). Both enantiomers raise dopamine levels in the nucleus accumbens in animals, reaching up to 150 to 200% of baseline at the highest doses tested, increases far smaller than those produced by amphetamine or cocaine. In animals the drug promotes wakefulness, maintaining it over a significantly longer timeframe than modafinil while perturbing sleep architecture to a lesser degree, with attenuated EEG power density in slow frequencies below 4 Hz and no sleep rebound.
Pharmacokinetics
The pharmacokinetics of flmodafinil are still under study. Unlike modafinil, flmodafinil does not induce cytochrome P450 enzymes, including CYP3A4 and CYP3A5.
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Harm Potential
History & Culture
Flmodafinil, also known by the developmental code names CRL-40,940, NLS-4, and JBG01-41, and by the alternative names bisfluoromodafinil and lauflumide, is a wakefulness-promoting agent related to modafinil. It appears to have first been patented in the 1980s, with a further patent granted in 2013.…
Legality
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the CRL-40-940 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.